Navigation Links
Neurobiological Technologies Reports Receipt of $2.0 Million Royalty Payment for Quarterly Sales of Memantine
Date:4/30/2008

EMERYVILLE, Calif., April 30 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: NTII), today announced it has received approximately $2.0 million from Merz Pharmaceuticals GmbH (Merz) for sales by Merz and its marketing partners of Memantine for the treatment of moderate-to-severe Alzheimer's disease during the quarter ended December 31, 2007. Under an exclusive marketing agreement, NTI currently receives quarterly royalty payments on certain sales of Memantine by Merz and its marketing partners.

About Neurobiological Technologies, Inc.

Neurobiological Technologies, Inc, (Nasdaq: NTII) is a biopharmaceutical company focused on developing novel, first-in-class agents for central nervous system conditions and other serious unmet medical needs. The Company's most advanced product candidate, Viprinex(TM) (ancrod), is in phase 3 clinical testing as a novel investigational drug for treating acute ischemic stroke. Viprinex has multiple mechanisms of action and is specifically designed to double the time period that patients can be treated after the onset of a stroke. Acute ischemic stroke is one of the most prevalent, debilitating and costly diseases in the world for which there are few acceptable treatment options. NTI's pipeline also includes a phase 3 investigational drug for brain swelling and other drug candidates in early-stage development for Alzheimer's and Huntington's diseases.


'/>"/>
SOURCE Neurobiological Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Neurobiological Technologies Appoints Matthew M. Loar as Chief Financial Officer
2. Neurobiological Technologies Announces Amendment of License and Cooperation Agreement with Merz Pharmaceuticals and Childrens Hospital
3. Neurobiological Technologies Reports $2.1 Million Quarterly Payment for Sales of Memantine
4. Neurobiological Technologies Sets Date for Research and Development Day
5. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q2/08 Review Issued By Scimitar Equity Research, Inc.
6. Update: Neurobiological Technologies Sets Date for Second Quarter Financial Results and Conference Call
7. Neurobiological Technologies Sets Date for Second Quarter Financial Results
8. Neurobiological Technologies, Inc. Reports Retirement of Ronald E. Cape, Ph.D., from Board
9. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q1/08 Review Issued By Scimitar Equity Research, Inc.
10. Neurobiological Technologies Announces Pricing of Its $60 Million Common Stock Offering
11. Neurobiological Technologies, Inc. (Nasdaq: NTIID)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/1/2017)... ... March 01, 2017 , ... ... will demonstrate how concentrating on protection, productivity and quality can help food and ... range of solutions – from x-ray and checkweighing to vision inspection and metal ...
(Date:3/1/2017)... 2017  Elizabeth Young and Joshua Rosenthal , ... Washington University,s Health Workforce Speaker series. http://bit.ly/2lA6C8B ... will be speaking on March 9, 2017 at the ... Washington, DC at 12:00pm. The ... renowned speakers to examine new workforce configurations, their outcomes ...
(Date:2/28/2017)... Diego, California (PRWEB) , ... ... ... Inc., the supplier of 3D nano-porous silicon biosensors and instruments for sensitive, ... and St. Marianna University, School of Medicine in Japan. The collaborators expect ...
(Date:2/28/2017)... , Feb. 28, 2017  Phosphorus, a ... today the formation of the Phosphorus Scientific Advisory ... experts chosen to advise the company on the ... multi-site research initiatives. Please visit http://phosphorus.com/about-us/ ... initiatives. "We,ve gathered some of the ...
Breaking Biology Technology:
(Date:2/8/2017)... 7, 2017 The biometrics market has ... confluence of organizations, desires to better authenticate or ... (password and challenge questions), biometrics is quickly working ... The market is driven by use cases, though ... and enterprise uses cases, with consumer-facing use cases ...
(Date:2/7/2017)... New York , February 7, 2017 ... as ID Global Solutions Corporation [OTC: IDGS], ("Ipsidy" or ... management and electronic transaction processing services, is pleased to ... of the Company. Effective January 31, 2017, ... the Board of Directors, CEO and President.  An experienced ...
(Date:2/2/2017)... , Feb. 2, 2017   TapImmune, Inc. ... immuno-oncology company specializing in the development of innovative ... treatment of cancer and metastatic disease, announced today ... GMP manufacturing of a second clinical lot of ... folate receptor alpha. The manufactured vaccine product will ...
Breaking Biology News(10 mins):